Investors
News Releases
GreenJay Appoints Lisa Bollinger, MD as Advisor
Houston, Texas — (March 4, 2026) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a late-stage pharmaceutical company developing potentially life-changing technologies for patients that require stem cell or bone...
Read MoreGreenJay Appoints Vassil Tzenov as Vice President and Chief Financial Officer
Houston, Texas — (December 2, 2025) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a late-stage pharmaceutics company developing potentially life-changing technologies for patients that require stem cell or bone marrow transplantation....
Read MoreGreenJay Therapeutics Successfully Closes $1 Million in its Series A Preferred Round of Financing
Capital Raise Fully Subscribed Houston, Texas — (October 21, 2025) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a drug formulation company focused on developing safer, more soluble and more efficacious...
Read MoreGreenJay Achieves Major Manufacturing Milestone for BULANTA™ as a Conditioning Agent for Stem Cell Transplantation
HOUSTON, Texas — (August 26, 2025) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a late-stage pharmaceutical company focused on developing life-changing therapies for patients requiring stem cell/bone marrow transplants, announced today...
Read MoreGreenJay Therapeutics Sadly Announces the Passing of Its CEO, Donald Payne
Houston, Texas – (July 30, 2025) – It is with great sadness that we announce the passing of our CEO and beloved friend, James Donald Payne (Donald) on the 13th...
Read MoreGreenJay Therapeutics Successfully Completes More than $1 Million in its Seed Round of Financing
Houston, Texas — (June 30, 2023) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a drug formulation company focused on developing safer, more soluble and more efficacious therapies for patients...
Read More